ClinicalTrials.gg
RecruitingNCT06150716Updated Dec 12, 2025

Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)

A Phase 1 interventional study of ION356 in Pelizaeus-Merzbacher Disease, sponsored by Ionis Pharmaceuticals, Inc.. Recruiting at 7 sites in 5 countries. Open to male participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
Male
01

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of ION356.

Read the detailed description

This is a Phase 1b, open-label multiple-ascending dose (MAD) study of ION356 in approximately 24 pediatric participants with Pelizaeus-Merzbacher Disease and genetic confirmation of proteolipid protein 1 (PLP1) gene duplication. The study will have 2 parts: a 48-week multiple-ascending dose (MAD) part followed by a long-term extension (LTE) part of 109 weeks. Eligible participants will receive doses of ION356 during the MAD portion of the study and upon completion will seamlessly transition to the open-label LTE to receive doses of ION356.

02

Conditions studied

  • Pelizaeus-Merzbacher Disease
03

In context

Lead sponsor

Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Participant's parent or legally accepted representative can provide , attend all scheduled study visits, provide feedback regarding the participant's symptoms, and can comply with all study requirements.
  2. Diagnosis of PMD with genetic confirmation of PLP1 gene duplication.
  3. Clinical phenotype and brain imaging consistent with a diagnosis of PMD.
  4. Male between the ages of 2 and 17 years, inclusive, at the time of informed consent.
  5. Able and willing to meet all study requirements (in the opinion of the Investigator), including travel to Study Center, procedures, measurements, and visits.

Exclusion Criteria

  1. abnormalities in medical history, laboratory tests or physical examination.
  2. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator.
  3. Any or unwillingness to undergo magnetic resonance imaging (MRI).
  4. Treatment with another drug, biological agent, or device within 1 month of Screening, or 5 half-lives of the investigational agent, whichever is longer.
  5. Previous treatment with an oligonucleotide (including small interfering ribonucleic acid) within 4 months of Screening if a single dose was received, or within 12 months of Screening if multiple doses were received. This exclusion does not apply to vaccines (both messenger ribonucleic acid [mRNA] and viral vector vaccines).
  6. History of gene therapy or cell transplantation, or any experimental brain surgery.
  7. Current obstructive hydrocephalus.
  8. Known brain or spinal disease or previous spinal surgery that would interfere with the lumbar puncture (LP) process, CSF circulation, or safety assessment.
  9. Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks prior to Screening or planned during the study.
  10. Have any other conditions, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort A: ION356 Dose A

    Participants will receive ION356 intrathecally at Dose A in the MAD Period, followed by ION356 Dose A in the LTE Period.

    Drug: ION356

  • Experimental
    Cohort B: ION356 Dose B

    Participants will receive ION356 intrathecally at Dose B in the MAD Period, followed by ION356 Dose B in the LTE Period.

    Drug: ION356

Interventions

  • DrugION356

    Administered as intrathecal (IT) injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: Up to Week 145

  2. Number of Participants With Clinically Significant Change from Baseline in Laboratory Assessments

    Time frame: Baseline up to Week 145

  3. Number of Participants With Clinically Significant Change From Baseline in Neurological Examination Findings

    Time frame: Baseline up to Week 145

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: Baseline up to Week 145

  5. Number of Participants With Clinically Significant Change From Baseline in Electrocardiography (ECG)

    Time frame: Baseline up to Week 145

  6. Number of Participants With Change From Baseline in Concomitant Medication Use

    Time frame: Baseline up to Week 145

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of ION356

    Time frame: Pre-dose and at multiple points post-dose up to Week 145

  2. Area Under the Concentration-time Curve (AUC) of ION356

    Time frame: Pre-dose and at multiple points post-dose up to Week 145

  3. Plasma Terminal Elimination Half-life (t½) of ION356

    Time frame: Pre-dose and at multiple points post-dose up to Week 145

  4. Plasma Concentration of ION356

    Time frame: Pre-dose and at multiple points post-dose up to Week 145

  5. Cerebrospinal Fluid (CSF) Concentration of ION356

    Time frame: Pre-dose and at multiple points post-dose up to Week 105

  6. Concentration of ION356 Excreted in Urine

    Time frame: Pre-dose and at multiple points post-dose on Week 1 and Week 49

  7. Percent of ION356 Dose Excreted in Urine

    Time frame: Pre-dose and at multiple points post-dose on Week 1 and Week 49

  8. Renal Clearance of ION356

    Time frame: Pre-dose and at multiple points post-dose on Week 1 and Week 49

07

Study locations

7 of 7 sites recruiting
  • Ionis Investigative Site
    Atlanta, Georgia 30342, United States
    Recruiting
  • Ionis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Ionis Investigative Site
    Salt Lake City, Utah 84113, United States
    Recruiting
  • Ionis Investigative Site
    Le Kremlin-Bicêtre, 94270, France
    Recruiting
  • Ionis Investigative Site
    Göttingen, 37075, Germany
    Recruiting
  • Ionis Investigative Site
    Tokyo, 187-8551, Japan
    Recruiting
  • Ionis Investigative Site
    Amsterdam, 1105AZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jun 2028, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Nov 29, 2023
StartActual
Apr 10, 2024
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06150716
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Apr 10, 2024
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Dec 12, 2025

Study contacts

Ionis Pharmaceuticals, Inc.
Contact
IonisPelizaeusMerzbacherStudy2@clinicaltrialmedia.com
(844) 387-9520

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion